Search company, investor...

Founded Year

1996

Stage

Acquired | Acquired

Total Raised

$4.84M

About Callisto Pharmaceuticals

Callisto Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and osteolytic bone disease, among other cancers. The Company's lead drug candidate, Atiprimod, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. The Company was formed, in April 2003, through a reverse acquisition between Callisto Pharmaceuticals and Webtronics. In January 2013, Callisto Pharmaceuticals was acquired by Synergy Pharmaceuticals. The valuation of Callisto Pharmaceuticals was undisclosed. Other terms of the deal were not released.

Headquarters Location

420 Lexington Avenue Suite 1609

New York, New York, 10170,

United States

212-297-0010

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Latest Callisto Pharmaceuticals News

OKYO Pharma Limited: Directorate Change

Dec 1, 2021

A Bernard F. Denoyer (age: 74) Bernard F. Denoyer has 49 years of financial management experience including his service as Senior Vice President, Finance and Secretary of development stage Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) from July 2008 until FDA approval and his retirement in June 2017. Mr. Denoyer concurrently served as Principal Financial Officer of Synergy’s former parent company, Callisto Pharmaceuticals, Inc. While with SGYP and CLSP he supported over $500M of public and PIPE financings with related due diligence, SEC registrations and market listings. From October 2000 to December 2003, Mr. Denoyer was an independent consultant, providing interim CFO and other services to emerging businesses, including Callisto and certain portfolio companies of Marsh & McLennan Capital, LLC. From October 1994 until September 2000, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc., an information technology research company. Mr. Denoyer earned his CPA with Ernst & Young in 1975. He received a Masters Certificate of Accounting from the Kellogg Graduate School of Management in 1974, an MBA in Finance with honors from Columbia Business School in 1972, and a BA in Economics from Fairfield University in 1969. Mr. Denoyer is fluent in French and studied in Paris at l’Istitut d’Etude Politique et Economique in 1968. He served in U.S. Army in Vietnam from 1969 to 1971 and has been an adjunct accounting professor at Fairfield University and the Marymount College. He is currently serving on the Board of Trustees for two 501(c)3 not-for-profits, St. Edmunds Retreat, Inc. and Midwestern Connecticut Council on Alcoholism, Inc. Mr Denoyer will assume the role chair the Nomination Committee of the Board from Mr Gabriele Cerrone (who will continue to serve as a member of the Nomination Committee). With immediate effect Willy Simon will assume the role of senior non-executive and will continue to chair the Remuneration Committee of the Board. Gabriele Cerrone, Chairman of OKYO, said, "We are delighted that Bernard has joined the Board of OKYO. His expertise will be of great value to us at a very important time for the group." There are no other disclosures to make pursuant to Listing Rule 9.6.13, in respect of Mr Denoyer's appointment. The person who approved the content of this announcement for purposes of UK MAR was Dr Gary Jacob, Chief Executive Officer. About OKYO OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Enquiries:

Callisto Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Callisto Pharmaceuticals founded?

    Callisto Pharmaceuticals was founded in 1996.

  • Where is Callisto Pharmaceuticals's headquarters?

    Callisto Pharmaceuticals's headquarters is located at 420 Lexington Avenue, New York.

  • What is Callisto Pharmaceuticals's latest funding round?

    Callisto Pharmaceuticals's latest funding round is Acquired.

  • How much did Callisto Pharmaceuticals raise?

    Callisto Pharmaceuticals raised a total of $4.84M.

  • Who are the investors of Callisto Pharmaceuticals?

    Investors of Callisto Pharmaceuticals include Synergy Pharmaceuticals, Anima, Ashton Partners, Banque Profil de Gestion S.A., New England Partners and 20 more.

  • Who are Callisto Pharmaceuticals's competitors?

    Competitors of Callisto Pharmaceuticals include Sierra Oncology, Sound Pharmaceuticals, Longevica, Portola Pharmaceuticals, ARIAD Pharmaceuticals and 14 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Callisto Pharmaceuticals to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Philogen Logo
Philogen

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications.

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

B
Bionovo

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

E
Escientia

is a contract research organization that collaborates with R&D departments of biotechnology and biopharmaceutical companies to discover and develop new medicines. The company also engages in its own drug discovery agenda to develop treatments of treat tropical diseases such as malaria.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.